Close Menu

Genisphere

NEW YORK (GenomeWeb News) – Genisphere said today it has licensed its 3DNA Signal Amplification technology to Chembio Diagnostics.

Quest Diagnostics has been awarded US Patent No. 8,346,485, "Methods and apparatuses for estimating initial target nucleic acid concentration in a sample by modeling background signal and cycle-dependent amplification efficiency of a polymerase chain reaction."

Genisphere and the Lankenau Institute for Medial Research said this week that they are expanding their collaboration on the development of microRNA biomarkers for ulcerative colitis to include Crohn's disease and other inflammatory bowel disorders.

NEW YORK (GenomeWeb News) –Genisphere and the Lankenau Institute for Medical Research today said that they have expanded their research collaboration aimed at identifying microRNA biomarkers to include Crohn's Disease and other inflammatory bowel disorders.

Hahn-Schickard-Gesellschaft of Villingen-Schwenningen, Germany, has received US Patent No.

NEW YORK (GenomeWeb News) – Affymetrix plans to offer Genisphere's miRNA reagents for use with its GeneChip miRNA 2.0 Arrays under a new license agreement, Affy said today.

Genisphere said this week that it has signed deals licensing its RNA target amplification and FlashTag Biotin microRNA labeling technologies to Affymetrix.

Quest Diagnostics, Albert Einstein College of Medicine, Riken, Genisphere, Stanford, DNA Electronics, US Genomics, Qiagen, and others awarded US patents.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.